ReviewPsychopharmacology2009
Role of cannabis and endocannabinoids in the genesis of schizophrenia.
Review in Psychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 149 citations in OpenAlex.
- The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)Pooled it
- Sensory gating in tobacco-naïve cannabis users is unaffected by acute nicotine administration.Psychopharmacology · 2022Trial
- Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.Journal of clinical psychopharmacology · 2011Trial
- Modern perspectives on psychoses: dissociation, automatism, and temporality across exogenous and endogenous dimensions.Frontiers in psychiatry · 2025Review
- Pyridoxine supplementation before puberty ameliorates MAM-induced cognitive and sensorimotor gating impairments.Metabolic brain disease · 2024Article
- Exploring causal mechanisms of psychosis risk.Neuroscience and biobehavioral reviews · 2024Review
- Rethinking Mental Automatism: De Clérambault's Theory in the Age of Novel Psychoactive Drugs: Psychotropic Effects and Synthetic Psychosis.Healthcare (Basel, Switzerland) · 2024Article
- Stress, Environment and Early Psychosis.Current neuropharmacology · 2024Review
- Article
- Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects.Schizophrenia bulletin · 2022Article
- A fluorescent sensor for spatiotemporally resolved imaging of endocannabinoid dynamics in vivo.Nature biotechnology · 2022Article
- The effects of preventative cannabidiol in a maleFrontiers in cellular neuroscience · 2022Article
- Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives.Frontiers in pharmacology · 2022Review
- Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis.Biological psychiatry · 2020Article
- Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.The EPMA journal · 2020Review
- In Vitro and In Vivo Models for the Investigation of Potential Drugs Against Schizophrenia.Biomolecules · 2020Review
- Are CB2 Receptors a New Target for Schizophrenia Treatment?Frontiers in psychiatry · 2020Review
- Medical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida.Journal of palliative medicine · 2019Article
- Non-Genetic Factors in Schizophrenia.Current psychiatry reports · 2019Review
- Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat.Schizophrenia research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCannabis abuse and endocannabinoids are associated to schizophrenia.
objectivesIt is important to discern the association between schizophrenia and exogenous Cannabis sativa, on one hand, and the endogenous cannabinoid system, on the other hand.
resultsOn one hand, there is substantial evidence that cannabis abuse is a risk factor for psychosis in genetically predisposed people, may lead to a worse outcome of the disease, or it can affect normal brain development during adolescence, increasing the risk for schizophrenia in adulthood. Regarding genetic predisposition, alterations affecting the cannabinoid CNR1 gene could be related to schizophrenia. On the other hand, the endogenous cannabinoid system is altered in schizophrenia (i.e., increased density of cannabinoid CB1 receptor binding in corticolimbic regions, enhanced cerebrospinal fluid anandamide levels), and dysregulation of this system can interact with neurotransmitter systems in such a way that a "cannabinoid hypothesis" can be integrated in the neurobiological hypotheses of schizophrenia. Finally, there is also evidence that some genetic alterations of the CNR1 gene can act as a protectant factor against schizophrenia or can induce a better pharmacological response to atypical antipsychotics.
conclusionsCannabis abuse is a risk factor for psychosis in predisposed people, it can affect neurodevelopment during adolescence leading to schizophrenia, and a dysregulation of the endocannabinoid system can participate in schizophrenia. It is also worth noting that some specific cannabinoid alterations can act as neuroprotectant for schizophrenia or can be a psychopharmacogenetic rather than a vulnerability factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.